Biotech Values

[Regulardoc]

No, but given how some PBMs are not covering Pradaxa for Afib, they will have internal challenges if they were to cover Xarelto for post-op ortho DVT prevention and NOT cover it, or similarly Pradaxa, for its other indication (in the future for Xarelto) for Afib. They could require a pre-authorization for using Xarelto in post-op DVT prevention if they wish not to cover it for any future Afib indication.

One way or another, a possible administrative nightmare and one filled with physician and patient dissatisfaction if the PBMs were to selectively allow any of these drugs for one FDA indication, yet not for another present, or future, FDA indication.

Purpose for making this point originally is that several PBMs are listing Pradaxa in the "non-covered" category for atrial fibrillation presently.